نتایج جستجو برای: Tenofovir

تعداد نتایج: 4096  

Tenofovir is an antiviral agent prescribed for patients suffering from hepatitis B. It is associated with some side effects such as reduction in the level of patients’ adherence. The aim of this study was to evaluate the impact of clinical pharmacist consultation on patients’ adherence to the use of Tenofovir. In this prospective study, a total of 80 patients were enrolled into the study and we...

Background:Tenofovir is among the first-line treatments for chronic hepatitis B (CHB) virus infection. We evaluated the efficacy of Tenofovir in the treatment of Iranian adult patients with CHB. Methods: In a retrospective study, we evaluated 154 HBsAg positive patients referred to Sadoughi hospital in Yazd-Iran for treatment ...

Journal: :The lancet. HIV 2017
Chloe Orkin Edwin DeJesus Moti Ramgopal Gordon Crofoot Peter Ruane Anthony LaMarca Anthony Mills Bernard Vandercam Joseph de Wet Jürgen Rockstroh Adriano Lazzarin Bart Rijnders Daniel Podzamczer Anders Thalme Marcel Stoeckle Danielle Porter Hui C Liu Andrew Cheng Erin Quirk Devi SenGupta Huyen Cao

BACKGROUND Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricit...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015
George K Siberry Denise L Jacobson Heidi J Kalkwarf Julia W Wu Linda A DiMeglio Ram Yogev Katherine M Knapp Justin J Wheeler Laurie Butler Rohan Hazra Tracie L Miller George R Seage Russell B Van Dyke Emily Barr Mariam Davtyan Lynne M Mofenson Kenneth C Rich

BACKGROUND Fetal bone effects of maternal tenofovir use have not been well studied. We sought to compare whole-body bone mineral content (BMC) of newborns exposed vs not exposed to tenofovir in utero. METHODS We enrolled participants from April 2011 to June 2013 at 14 US clinical sites. Singleton infants of women with human immunodeficiency virus (HIV) infection who took tenofovir in late pre...

Journal: :The Journal of antimicrobial chemotherapy 2012
Pedro M M Mesquita Rachna Rastogi Theodore J Segarra Ryan S Teller N Merna Torres Ashley M Huber Patrick F Kiser Betsy C Herold

OBJECTIVES A safe and effective topical prevention strategy will likely require sustained delivery of potent antiviral drugs and a delivery system that simultaneously maximizes drug distribution and overcomes the behavioural challenges related to adherence. Activity against HIV and herpes simplex virus (HSV) would be advantageous, given the epidemiological link between the two pathogens. We hyp...

Journal: :archives of clinical infectious diseases 0
masoud mardani infectious diseases and tropical medicine research center, shahid beheshti university of medical sciences, tehran, ir iran; infectious diseases and tropical medicine research center, shahid beheshti university of medical sciences, tehran, ir iran. tel.: +98-2122439963, fax: +98-22439964, e-mail: [email protected]

Journal: :Antimicrobial agents and chemotherapy 2006
William E Delaney Adrian S Ray Huiling Yang Xiaoping Qi Shelly Xiong Yuao Zhu Michael D Miller

Tenofovir is an acyclic nucleotide analog with activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Tenofovir disoproxil fumarate (tenofovir DF), a bis-alkoxyester prodrug of tenofovir, is approved for the treatment of HIV and is currently being developed to treat chronic hepatitis B. In this report, we further characterize the in vitro activity of tenofovir against ...

2014
Andrew Hill Saye Khoo David Back Anton Pozniak Marta Boffito

INTRODUCTION The approved dose of tenofovir disproxil fumarate, 300 mg once daily, was established in clinical trials in combination with efavirenz, which does not significantly affect tenofovir concentrations. Combining tenofovir with lopinavir/r, darunavir/r or atazanavir/r increases tenofovir concentrations, which could raise the risk of renal adverse events. Newly approved tenofovir tablets...

2011
Michael Martin Suphak Vanichseni Pravan Suntharasamai Udomsak Sangkum Rutt Chuachoowong Philip A. Mock Manoj Leethochawalit Sithisat Chiamwongpaet Somyot Kittimunkong Frits van Griensven Janet M. McNicholl Lynn Paxton Kachit Choopanya

BACKGROUND The Bangkok Tenofovir Study was launched in 2005 to determine if pre-exposure prophylaxis with tenofovir will reduce the risk of HIV infection among injecting drug users (IDUs). We describe recruitment, screening, enrollment, and baseline characteristics of study participants and contrast risk behavior of Tenofovir Study participants with participants in the 1999-2003 AIDSVAX B/E Vac...

Journal: :Lancet 2015
Paul E Sax David Wohl Michael T Yin Frank Post Edwin DeJesus Michael Saag Anton Pozniak Melanie Thompson Daniel Podzamczer Jean Michel Molina Shinichi Oka Ellen Koenig Benoit Trottier Jaime Andrade-Villanueva Gordon Crofoot Joseph M Custodio Andrew Plummer Lijie Zhong Huyen Cao Hal Martin Christian Callebaut Andrew K Cheng Marshall W Fordyce Scott McCallister

BACKGROUND Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens. METHODS In ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید